Haitao Wang, Ph.D
Tianjin Medical University Second Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Haitao Wang, Ph.D as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:00 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07917351 · AI-Assisted Whole-Course Management for Medication Safety and Healthcare Burden in Advanced Solid Tumors: A Prospective Controlled StudyTianjin Medical University Second Hospital · recruiting · Digital Health, Artificial Intelligence (AI) · principal investigator
- N/ANCT07906301 · Organoid Drug Sensitivity-Guided Therapy for Refractory TumorsTianjin Medical University Second Hospital · recruiting · Refractory Tumors, Organoid · study chair
- Ph2NCT07712029 · Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveTianjin Medical University Second Hospital · recruiting · Advanced Refractory Solid Tumors, EGFR Gene Overexpression · principal investigator
- Ph2NCT07179783 · Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)Tianjin Medical University Second Hospital · recruiting · Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation · study chair
- Ph2NCT07170293 · Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid TumorsTianjin Medical University Second Hospital · recruiting · Solid Cancers · principal investigator
- Ph2NCT06739395 · Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionTianjin Medical University Second Hospital · recruiting · Solid Tumor, Precision Medicine · principal investigator
- N/ANCT06030869 · MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid TumorsTianjin Medical University Second Hospital · unknown · Refractory Solid Tumors, Next Generation Sequencing · principal investigator
- Ph2NCT06022289 · Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification · principal investigator
- N/ANCT06022276 · Nimotuzumab for EGFR-amplified Advanced Pan Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, EGFR Amplification · principal investigator
- N/ANCT06009835 · DOTr/DOTa Algorithm Guidance for Refractory Solid TumorsTianjin Medical University Second Hospital · unknown · Solid Tumor, Individuation · principal investigator
- Ph1NCT03645200 · Treatment of Carrying TP53 Harmful MutationsTianjin Medical University Second Hospital · unknown · Advanced Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.